Zydus receives final approval from the USFDA for Tadalafil Tablets USP, 20 mg

Zydus receives final approval from the USFDA for Tadalafil Tablets USP, 20 mg Ahmedabad, India, 7 June, 2023 Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) for Tadalafil Tablets USP, 20 mg (USRLD: Adcirca Tablets, 20 mg). Tadalafil relaxes muscles of the blood vessels and increases blood flow to particular areas of the body. It is used to treat pulmonary arterial hypertension and improve exercise capacity in men and women. The product will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India). Tadalafil Tablets USP, 20 mg had annual sales of USD 61 mn in the United States (IQVIA MAT April 2023). The group now has 369 approvals and has so far filed over 44 2* ANDAs since the commencement of the filing process in FY 2003-04. (*as of 31st March 2023) ***

The release as fetched from its publisher. zyduslife.com ↗